

Anurag S Rathore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5226047/publications.pdf>

Version: 2024-02-01

263
papers

6,646
citations

81900

39
h-index

95266

68
g-index

287
all docs

287
docs citations

287
times ranked

3986
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 158-171.	1.1	0
2	RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6039-6051.	3.5	29
3	Contribution of protein A step towards cost of goods for continuous production of monoclonal antibody therapeutics. <i>Journal of Chemical Technology and Biotechnology</i> , 2022, 97, 2420-2433.	3.2	13
4	The global landscape on interchangeability of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 133-148.	3.1	7
5	Current status and future challenges in transitioning to continuous bioprocessing of virus-like particles. <i>Journal of Chemical Technology and Biotechnology</i> , 2022, 97, 2376-2385.	3.2	11
6	Ion Exchange Chromatographic Methods for of. <i>Methods in Molecular Biology</i> , 2022, 2313, 179-186.	0.9	0
7	Need for a risk-based control strategy for managing glycosylation profile for biosimilar products. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 123-131.	3.1	3
8	Multi-wavelength UV-based PAT tool for measuring protein concentration. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114394.	2.8	10
9	Applications of capillary electrophoresis for biopharmaceutical product characterization. <i>Electrophoresis</i> , 2022, 43, 143-166.	2.4	25
10	Purification of Therapeutic Antibodies by Protein A Affinity Chromatography. <i>Methods in Molecular Biology</i> , 2022, 2313, 169-177.	0.9	3
11	Biomass to fuels and chemicals: A review of enabling processes and technologies. <i>Journal of Chemical Technology and Biotechnology</i> , 2022, 97, 597-607.	3.2	16
12	Ethanol as additive enhances expression of Ranibizumab in <i>Escherichia coli</i> : Impact on cellular physiology and transcriptome. <i>Process Biochemistry</i> , 2022, 112, 167-176.	3.7	3
13	Biopharmaceutical Industry Capability Building in India: Report from a Symposium. <i>Journal of Pharmaceutical Innovation</i> , 2022, 17, 1555-1562.	2.4	3
14	Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. <i>Molecular Diversity</i> , 2022, 26, 2613-2629.	3.9	4
15	Enablers of continuous processing of biotherapeutic products. <i>Trends in Biotechnology</i> , 2022, 40, 804-815.	9.3	12
16	Cole modeling of real-time capacitance data for estimation of cell physiological properties in recombinant <i>Escherichia coli</i> cultivation. <i>Biotechnology and Bioengineering</i> , 2022, 119, 922-935.	3.3	7
17	Slow post-induction specific growth rate enhances recombinant protein expression in <i>Escherichia coli</i> : Pramlintide multimer and ranibizumab production as case studies. <i>Process Biochemistry</i> , 2022, 114, 21-27.	3.7	4
18	Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19. <i>International Journal of Biological Macromolecules</i> , 2022, 200, 428-437.	7.5	15

#	ARTICLE	IF	CITATIONS
19	Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 832059.	4.1	21
20	Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 903-918.	3.3	45
21	A Charge Variant of Bevacizumab Offers Enhanced FcRn-Dependent Pharmacokinetic Half-Life and Efficacy. <i>Pharmaceutical Research</i> , 2022, 39, 851-865.	3.5	3
22	Raman spectroscopy as process analytical technology tool for monitoring atomic layer deposition (ALD) of drug particles. <i>Materials Chemistry and Physics</i> , 2022, 282, 125976.	4.0	3
23	NMR based quality evaluation of mAb therapeutics: A proof of concept higher order structure biosimilarity assessment of trastuzumab biosimilars. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 214, 114710.	2.8	1
24	Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review. <i>AAPS Journal</i> , 2022, 24, 15.	4.4	4
25	Unexplored Excipients in Biotherapeutic Formulations: Natural Osmolytes as Potential Stabilizers Against Thermally Induced Aggregation of IgG1 Biotherapeutics. <i>AAPS PharmSciTech</i> , 2022, 23, 26.	3.3	8
26	Challenges in Expression and Purification of Functional Fab Fragments in <i>E. coli</i> : Current Strategies and Perspectives. <i>Fermentation</i> , 2022, 8, 175.	3.0	9
27	N-Glycosylation of monoclonal antibody therapeutics: A comprehensive review on significance and characterization. <i>Analytica Chimica Acta</i> , 2022, 1209, 339828.	5.4	23
28	Achieving charge variant profile of innovator molecule during development of monoclonal antibody based biosimilars – Use of media components. <i>Biochemical Engineering Journal</i> , 2022, 182, 108438.	3.6	1
29	Dynamics of biosimilar uptake in emerging markets. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 679-688.	3.1	2
30	Optimization of multi flow rate loading strategy for process intensification of Protein A chromatography. <i>Journal of Chromatography Open</i> , 2022, 2, 100049.	2.2	3
31	Atomic Layer Deposition Coating on the Surface of Active Pharmaceutical Ingredients to Reduce Surface Charge Build-Up. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 27195-27202.	8.0	3
32	Process Analytical Technology (PAT) Implementation for Membrane Operations in Continuous Manufacturing of mAbs: Model-Based Control of Single-Pass Tangential Flow Ultrafiltration. <i>AAPS Journal</i> , 2022, 24, .	4.4	5
33	AI-ML applications in bioprocessing: ML as an enabler of real time quality prediction in continuous manufacturing of mAbs. <i>Computers and Chemical Engineering</i> , 2022, 164, 107896.	3.8	16
34	Approval of biosimilars: a review of unsuccessful regulatory filings. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 19-28.	3.1	8
35	Reinforcement learning based optimization of process chromatography for continuous processing of biopharmaceuticals. <i>Chemical Engineering Science</i> , 2021, 230, 116171.	3.8	31
36	Process analytical technology application for protein PEGylation using near infrared spectroscopy: G-CSF as a case study. <i>Journal of Biotechnology</i> , 2021, 325, 303-311.	3.8	8

#	ARTICLE	IF	CITATIONS
37	Monitoring size and oligomeric-state distribution of therapeutic mAbs by NMR and DLS: Trastuzumab as a case study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 195, 113841.	2.8	5
38	<scp>COVIDâ€19</scp> pandemic: mechanism, diagnosis, and treatment. <i>Journal of Chemical Technology and Biotechnology</i> , 2021, 96, 299-308.	3.2	20
39	Economic assessment of continuous processing for manufacturing of biotherapeutics. <i>Biotechnology Progress</i> , 2021, 37, e3108.	2.6	23
40	Identification and characterization of carbonylation sites in trastuzumab biosimilars. <i>International Journal of Biological Macromolecules</i> , 2021, 169, 95-102.	7.5	4
41	Modulation of <scp>granulocyte colony stimulating factor</scp> conformation and receptor binding by methionine oxidation. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 68-80.	2.6	2
42	Regulatory considerations in biosimilars: Asia pacific regions. <i>Preparative Biochemistry and Biotechnology</i> , 2021, 51, 1-8.	1.9	9
43	LCâ€MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity. <i>Scientific Reports</i> , 2021, 11, 2487.	3.3	17
44	Considerations related to comparative clinical studies for biosimilars. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 265-274.	2.4	1
45	Regulatory considerations in biosimilars: Latin America region. <i>Preparative Biochemistry and Biotechnology</i> , 2021, 51, 201-206.	1.9	5
46	Challenges in process control for continuous processing for production of monoclonal antibody products. <i>Current Opinion in Chemical Engineering</i> , 2021, 31, 100671.	7.8	29
47	A novel reactor configuration for continuous virus inactivation. <i>Biochemical Engineering Journal</i> , 2021, 167, 107885.	3.6	14
48	Control of surge tanks for continuous manufacturing of monoclonal antibodies. <i>Biotechnology and Bioengineering</i> , 2021, 118, 1913-1931.	3.3	16
49	Complete or periodic continuity in continuous manufacturing platforms for production of monoclonal antibodies?. <i>Biotechnology Journal</i> , 2021, 16, e2000524.	3.5	14
50	Raman spectroscopy for in situ, real time monitoring of protein aggregation in lyophilized biotherapeutic products. <i>International Journal of Biological Macromolecules</i> , 2021, 179, 309-313.	7.5	10
51	CFD based mass transfer modeling of a single use bioreactor for production of monoclonal antibody biotherapeutics. <i>Chemical Engineering Journal</i> , 2021, 412, 128592.	12.7	29
52	Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120456.	5.2	13
53	Effect of vitamins and metal ions on productivity and charge heterogeneity of IgG1 expressed in CHO cells. <i>Biotechnology Journal</i> , 2021, 16, e2000464.	3.5	7
54	Novel semi-automated fluorescence microscope imaging algorithm for monitoring IgG aggregates in serum. <i>Scientific Reports</i> , 2021, 11, 11375.	3.3	4

#	ARTICLE	IF	CITATIONS
55	A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus. <i>Scientific Reports</i> , 2021, 11, 11723.	3.3	7
56	Bioprocess Control: Current Progress and Future Perspectives. <i>Life</i> , 2021, 11, 557.	2.4	43
57	A simple, rapid, and robust "one-step" identity testing of biotherapeutics using FTIR spectroscopy. <i>Electrophoresis</i> , 2021, 42, 1655-1664.	2.4	2
58	Supplementation of critical amino acids improves glycerol and lactose uptake and enhances recombinant protein production in <i>Escherichia coli</i> . <i>Biotechnology Journal</i> , 2021, 16, e2100143.	3.5	5
59	A chemical engineer's take of COVID-19 epidemiology. <i>AIChE Journal</i> , 2021, 67, e17359.	3.6	1
60	Freeze thaw and lyophilization induced alteration in mAb therapeutics: Trastuzumab as a case study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 201, 114122.	2.8	6
61	Checking counterfeiting of pharmaceutical products by attenuated total reflection mid-infrared spectroscopy. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 255, 119710.	3.9	0
62	Regulatory considerations in biosimilars: Middle East and Africa regions. <i>Preparative Biochemistry and Biotechnology</i> , 2021, 51, 731-737.	1.9	8
63	Process development in the QbD paradigm: Implementing design of experiments (DoE) in anti-solvent crystallization for production of pharmaceuticals. <i>Journal of Crystal Growth</i> , 2021, 571, 126263.	1.5	4
64	Rapid aggregation of therapeutic monoclonal antibodies by bubbling induced air/liquid interfacial and agitation stress at different conditions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 168, 97-109.	4.3	12
65	Mechanistic modelling of Chinese hamster ovary cell clarification using acoustic wave separator. <i>Chemical Engineering Science</i> , 2021, 246, 116894.	3.8	6
66	Harnessing the power of electrophoresis and chromatography: Offline coupling of reverse phase liquid chromatography-capillary zone electrophoresis-tandem mass spectrometry for analysis of host cell proteins in monoclonal antibody producing CHO cell line. <i>Electrophoresis</i> , 2021, 42, 735-741.	2.4	13
67	Synergistic Effects of Natural Compounds Toward Inhibition of SARS-CoV-2 3CL Protease. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5708-5718.	5.4	8
68	Image Analysis Algorithm-Based Platform for Determining Micron and Higher Aggregate Size Distribution of Therapeutic IgG Using Brightfield and Fluorescence Microscope Images. <i>Pharmaceutical Research</i> , 2021, 38, 1747-1763.	3.5	2
69	Process analytical technology in continuous processing: Model-based real time control of pH between capture chromatography and viral inactivation for monoclonal antibody production. <i>Journal of Chromatography A</i> , 2021, 1658, 462614.	3.7	5
70	Cyclodextrins as modulators for separation of charged variants of mAbs by capillary zone electrophoresis. <i>Journal of Chromatography Open</i> , 2021, 1, 100011.	2.2	0
71	High-Throughput Process Development: "Process Chromatography. <i>Methods in Molecular Biology</i> , 2021, 2178, 11-20.	0.9	0
72	High-Throughput Process Development: "Membrane Chromatography. <i>Methods in Molecular Biology</i> , 2021, 2178, 21-26.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Aqueous Two-Phase-Assisted Precipitation of Proteins: A Platform for Isolation of Process-Related Impurities from Therapeutic Proteins. <i>Methods in Molecular Biology</i> , 2021, 2178, 81-91.	0.9	0
74	Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars. <i>Journal of Diabetes Science and Technology</i> , 2021, , 193229682110584.	2.2	4
75	Neural network-based fingerprinting of monoclonal antibody aggregation using biolayer interferometry. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 2177-2186.	3.7	4
76	Process intensification in peptide manufacturing: Recombinant lethal toxin neutralizing factor (rLTNF) as a case study. <i>Process Biochemistry</i> , 2020, 90, 193-203.	3.7	1
77	Understanding the mechanism of copurification of difficult to remove host cell proteins in rituximab biosimilar products. <i>Biotechnology Progress</i> , 2020, 36, e2936.	2.6	14
78	Population balance modelling of aggregation of monoclonal antibody based therapeutic proteins. <i>Chemical Engineering Science</i> , 2020, 216, 115479.	3.8	5
79	Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 110, 104525.	2.7	11
80	An NIR-based PAT approach for real-time control of loading in Protein A chromatography in continuous manufacturing of monoclonal antibodies. <i>Biotechnology and Bioengineering</i> , 2020, 117, 673-686.	3.3	46
81	Modeling and prediction of excipient and pH drifts during ultrafiltration/diafiltration of monoclonal antibody biotherapeutic for high concentration formulations. <i>Separation and Purification Technology</i> , 2020, 238, 116392.	7.9	15
82	Does interaction of monoclonal antibody charge variants with VEGF-A and ELISA reagents affect its quantification?. <i>Analytical Biochemistry</i> , 2020, 590, 113513.	2.4	6
83	Engineering Staphylococcal Protein A for high-throughput affinity purification of monoclonal antibodies. <i>Biotechnology Advances</i> , 2020, 44, 107632.	11.7	18
84	Phosphate starvation controls lactose metabolism to produce recombinant protein in <i>Escherichia coli</i> . <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 9707-9718.	3.6	6
85	Understanding Oxidation Propensity in GCSF and Assessment of its Safety and Efficacy. <i>Pharmaceutical Research</i> , 2020, 37, 207.	3.5	2
86	Multiobjective Optimization for Enhanced Production of Therapeutic Proteins in <i>Escherichia coli</i> : Application of Real-Time Dielectric Spectroscopy. <i>Industrial & Engineering Chemistry Research</i> , 2020, 59, 21841-21853.	3.7	5
87	Development of an integrated continuous PEGylation and purification Process for granulocyte colony stimulating factor. <i>Journal of Biotechnology</i> , 2020, 322, 79-89.	3.8	15
88	Implementing PAT for single-pass tangential flow ultrafiltration for continuous manufacturing of monoclonal antibodies. <i>Journal of Membrane Science</i> , 2020, 613, 118492.	8.2	27
89	Automation of Dead End Filtration: An Enabler for Continuous Processing of Biotherapeutics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 758.	4.1	16
90	The selection of highly specific and selective aptamers using modified SELEX and their use in process analytical techniques for Lucentis bioproduction. <i>RSC Advances</i> , 2020, 10, 28906-28917.	3.6	8

#	ARTICLE	IF	CITATIONS
91	Amino acid supplementation for enhancing recombinant protein production in <i>E. coli</i> . <i>Biotechnology and Bioengineering</i> , 2020, 117, 2420-2433.	3.3	25
92	Microaerobic fermentation alters lactose metabolism in <i>Escherichia coli</i> . <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 5773-5785.	3.6	8
93	Impact of mAb Aggregation on Its Biological Activity: Rituximab as a Case Study. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2684-2698.	3.3	21
94	Covid 19 pandemic in India. <i>Journal of Chemical Technology and Biotechnology</i> , 2020, 95, 1841-1841.	3.2	5
95	Process Analytical Technology Implementation for Peptide Manufacturing: Cleavage Reaction of Recombinant Lethal Toxin Neutralizing Factor Concatemer as a Case Study. <i>Analytical Chemistry</i> , 2020, 92, 5676-5681.	6.5	1
96	Effect of chemically defined growth medium components on characteristics of bacterial inclusion bodies. <i>Journal of Chemical Technology and Biotechnology</i> , 2020, 95, 1640-1648.	3.2	3
97	Mechanistic explanation of structural and functional changes induced by methionine mutation in G-CSF protein. <i>Current Research in Biotechnology</i> , 2020, 2, 37-44.	3.7	0
98	Harnessing the power of electrophoresis and chromatography: Offline coupling of reverse phase liquid chromatography-capillary zone electrophoresis-tandem mass spectrometry for peptide mapping for monoclonal antibodies. <i>Journal of Chromatography A</i> , 2020, 1620, 460954.	3.7	16
99	Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. <i>BioDrugs</i> , 2020, 34, 209-223.	4.6	22
100	An application of Nano Differential Scanning Fluorimetry for Higher Order Structure assessment between mAb originator and biosimilars: Trastuzumab and Rituximab as case studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113270.	2.8	11
101	Pretreatments for enhancing clarification efficiency of depth filtration during production of monoclonal antibody therapeutics. <i>Biotechnology Progress</i> , 2020, 36, e2996.	2.6	7
102	Structure-Based Design of Small Peptide Ligands to Inhibit Early-Stage Protein Aggregation Nucleation. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 3304-3314.	5.4	12
103	Polymer-Coated Fiber Optic Sensor as a Process Analytical Tool for Biopharmaceutical Impurity Detection. <i>IEEE Transactions on Instrumentation and Measurement</i> , 2020, 69, 7666-7674.	4.7	5
104	Role of data science in managing COVID-19 pandemic. <i>Indian Chemical Engineer</i> , 2020, 62, 385-395.	1.5	8
105	Implementing Process Analytical Technology for the Production of Recombinant Proteins in <i>Escherichia coli</i> Using an Advanced Controller Scheme. <i>Biotechnology Journal</i> , 2019, 14, 1800556.	3.5	5
106	Analytical tools for monitoring changes in physical and chemical properties of chromatography resin upon reuse. <i>Electrophoresis</i> , 2019, 40, 3074-3083.	2.4	3
107	A novel approach for protein identification from complex cell proteome using modified peptide mass fingerprinting algorithm. <i>Electrophoresis</i> , 2019, 40, 3062-3073.	2.4	0
108	Analytical Platform for Monitoring Aggregation of Monoclonal Antibody Therapeutics. <i>Pharmaceutical Research</i> , 2019, 36, 152.	3.5	37

#	ARTICLE	IF	CITATIONS
109	An overview of mechanistic modeling of liquid chromatography. <i>Preparative Biochemistry and Biotechnology</i> , 2019, 49, 623-638.	1.9	35
110	QbD Based Media Development for the Production of Fab Fragments in <i>E. coli</i> . <i>Bioengineering</i> , 2019, 6, 29.	3.5	16
111	The influence of domestic manufacturing capabilities on biologic pricing in emerging economies. <i>Nature Biotechnology</i> , 2019, 37, 498-501.	17.5	18
112	Usability of NISTmAb reference material for biosimilar analytical development. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 2867-2883.	3.7	4
113	High performance liquid chromatography (HPLC) based direct and simultaneous estimation of excipients in biopharmaceutical products. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1117, 118-126.	2.3	7
114	Shadow pricing and the art of profiteering from outdated therapies. <i>Nature Biotechnology</i> , 2019, 37, 217-220.	17.5	5
115	Process analytical technology implementation for protein refolding: GCSF as a case study. <i>Biotechnology and Bioengineering</i> , 2019, 116, 1039-1052.	3.3	20
116	Mechanistic modeling based process analytical technology implementation for pooling in hydrophobic interaction chromatography. <i>Biotechnology Progress</i> , 2019, 35, e2758.	2.6	7
117	Design, preparation, and evaluation of liposomal gel formulations for treatment of acne: <i>in vitro</i> and <i>in vivo</i> studies. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 395-404.	2.0	36
118	Design of experiments applications in bioprocessing: Chromatography process development using split design of experiments. <i>Biotechnology Progress</i> , 2019, 35, e2730.	2.6	14
119	Comparison and implementation of different control strategies for improving production of rHSA using <i>Pichia pastoris</i> . <i>Journal of Biotechnology</i> , 2019, 290, 33-43.	3.8	11
120	Stability of Therapeutic Enzymes: Challenges and Recent Advances. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 131-150.	1.6	4
121	Approval of Ogivri. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2018, 72, 1-1.	0.5	2
122	Lifetime and Aging of Chromatography Resins during Biopharmaceutical Manufacture. <i>Trends in Biotechnology</i> , 2018, 36, 992-995.	9.3	20
123	Application of CFD in Bioprocessing: Separation of mammalian cells using disc stack centrifuge during production of biotherapeutics. <i>Journal of Biotechnology</i> , 2018, 267, 1-11.	3.8	19
124	Process for production and purification of lethal toxin neutralizing factor (LTNF) from <i>E. coli</i> and its economic analysis. <i>Journal of Chemical Technology and Biotechnology</i> , 2018, 93, 959-967.	3.2	4
125	Role of raw materials in biopharmaceutical manufacturing: risk analysis and fingerprinting. <i>Current Opinion in Biotechnology</i> , 2018, 53, 99-105.	6.6	17
126	Protein A chromatography resin lifetime—impact of feed composition. <i>Biotechnology Progress</i> , 2018, 34, 412-419.	2.6	12

#	ARTICLE	IF	CITATIONS
127	Process Development in the QbD Paradigm: Mechanistic Modeling of Antisolvent Crystallization for Production of Pharmaceuticals. <i>Crystal Growth and Design</i> , 2018, 18, 3352-3359.	3.0	6
128	Recent developments in chromatographic purification of biopharmaceuticals. <i>Biotechnology Letters</i> , 2018, 40, 895-905.	2.2	64
129	Enhanced product understanding in the QbD paradigm: linkage between charge heterogeneity and stability of monoclonal antibody therapeutic products. <i>Journal of Chemical Technology and Biotechnology</i> , 2018, 93, 2102-2110.	3.2	2
130	Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. <i>MAbs</i> , 2018, 10, 143-158.	5.2	46
131	Process Analysis: High Performance Liquid Chromatography. , 2018, , .		3
132	Development and Commercialization of Biosimilars in India: Current Regulatory and Clinical Experience. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2018, , 653-674.	0.6	0
133	Process integration and control in continuous bioprocessing. <i>Current Opinion in Chemical Engineering</i> , 2018, 22, 18-25.	7.8	41
134	Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. <i>Journal of Chromatography A</i> , 2018, 1579, 60-72.	3.7	35
135	Implementation of QbD for Manufacturing of Biologicsâ€”Has It Met the Expectations?. , 2018, , 1051-1073.		2
136	Kinetics and Characterization of Non-enzymatic Fragmentation of Monoclonal Antibody Therapeutics. <i>Pharmaceutical Research</i> , 2018, 35, 142.	3.5	11
137	Use of HPLC as an Enabler of Process Analytical Technology in Process Chromatography. <i>Analytical Chemistry</i> , 2018, 90, 7824-7829.	6.5	41
138	Process development in the Quality by Design paradigm: Modeling of Protein A chromatography resin fouling. <i>Journal of Chromatography A</i> , 2018, 1570, 56-66.	3.7	11
139	Mechanistic modeling of hydrophobic interaction chromatography for monoclonal antibody purification: process optimization in the quality by design paradigm. <i>Journal of Chemical Technology and Biotechnology</i> , 2018, 93, 2784-2784.	3.2	2
140	Monitoring and Control of Bioethanol Production From Lignocellulosic Biomass. , 2018, , 727-749.		10
141	Multimodal Chromatography for Purification of Biotherapeutics â€” A Review. <i>Current Protein and Peptide Science</i> , 2018, 20, 4-13.	1.4	42
142	Continuous Processing To Enable Manufacturing Of Affordable Biotherapeutics. , 2018, , .		0
143	Optimization of ion exchange sigmoidal gradients using hybrid models: Implementation of quality by design in analytical method development. <i>Journal of Chromatography A</i> , 2017, 1491, 145-152.	3.7	18
144	Implementation of quality by design toward processing of food products. <i>Preparative Biochemistry and Biotechnology</i> , 2017, 47, 435-440.	1.9	10

#	ARTICLE	IF	CITATIONS
145	Mechanistic modeling of hydrophobic interaction chromatography for monoclonal antibody purification: process optimization in the quality by design paradigm. <i>Journal of Chemical Technology and Biotechnology</i> , 2017, 92, 2527-2537.	3.2	9
146	Fluorescence based real time monitoring of fouling in process chromatography. <i>Scientific Reports</i> , 2017, 7, 45640.	3.3	9
147	Cover Image, Volume 92, Issue 4. <i>Journal of Chemical Technology and Biotechnology</i> , 2017, 92, i-i.	3.2	0
148	<sc>ATF</sc> for cell culture harvest clarification: mechanistic modelling and comparison with <sc>TFF</sc>. <i>Journal of Chemical Technology and Biotechnology</i> , 2017, 92, 732-740.	3.2	26
149	Integrated continuous processing of proteins expressed as inclusion bodies: GCSF as a case study. <i>Biotechnology Progress</i> , 2017, 33, 998-1009.	2.6	32
150	Integrated Chromatographic Platform for Simultaneous Separation of Charge Variants and Aggregates from Monoclonal Antibody Therapeutic Products. <i>Biotechnology Journal</i> , 2017, 12, 1700133.	3.5	26
151	Peptide Dendrons as Thermal-Stability Amplifiers for Immunoglobulin G1 Monoclonal Antibody Biotherapeutics. <i>Bioconjugate Chemistry</i> , 2017, 28, 2549-2559.	3.6	14
152	Determination of Critical Quality Attributes for a Biotherapeutic in the QbD Paradigm: GCSF as a Case Study. <i>AAPS Journal</i> , 2017, 19, 1826-1841.	4.4	11
153	A three plus three parameters mechanistic model for viral filtration. <i>Biotechnology Progress</i> , 2017, 33, 1538-1547.	2.6	2
154	Mechanistic Modeling Based PAT Implementation for Ionâ€Exchange Process Chromatography of Charge Variants of Monoclonal Antibody Products. <i>Biotechnology Journal</i> , 2017, 12, 1700286.	3.5	21
155	Implementation of a fluorescence based PAT control for fouling of protein A chromatography resin. <i>Journal of Chemical Technology and Biotechnology</i> , 2017, 92, 2799-2807.	3.2	8
156	Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals. <i>Pharmaceutical Research</i> , 2017, 34, 243-256.	3.5	14
157	Enabler for process analytical technology implementation in <i>Pichia pastoris</i> fermentation: Fluorescenceâ€based soft sensors for rapid quantitation of product titer. <i>Engineering in Life Sciences</i> , 2017, 17, 448-457.	3.6	6
158	Economic benefits of membrane chromatography versus packed bed column purification of therapeutic proteins expressed in microbial and mammalian hosts. <i>Journal of Chemical Technology and Biotechnology</i> , 2017, 92, 59-68.	3.2	20
159	Opossum peptide that can neutralize rattlesnake venom is expressed in <sc>E</sc> <sc>schlerichia coli</sc>. <i>Biotechnology Progress</i> , 2017, 33, 81-86.	2.6	17
160	CFD of mixing of multiâ€phase flow in a bioreactor using population balance model. <i>Biotechnology Progress</i> , 2016, 32, 613-628.	2.6	42
161	Process development in the <sc>Q</sc><sc>D</sc> paradigm: Role of process integration in process optimization for production of biotherapeutics. <i>Biotechnology Progress</i> , 2016, 32, 355-362.	2.6	20
162	Knowledge management in a waste based biorefinery in the QbD paradigm. <i>Bioresource Technology</i> , 2016, 215, 63-75.	9.6	13

#	ARTICLE	IF	CITATIONS
163	Implementation of Quality by Design for processing of food products and biotherapeutics. Food and Bioproducts Processing, 2016, 99, 231-243.	3.6	15
164	Analytical characterization of in vitro refolding in the quality by design paradigm: Refolding of recombinant human granulocyte colony stimulating factor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 126, 124-131.	2.8	16
165	Monitoring Quality of Biotherapeutic Products Using Multivariate Data Analysis. AAPS Journal, 2016, 18, 793-800.	4.4	8
166	Glycosylation of monoclonal antibody products: Current status and future prospects. Biotechnology Progress, 2016, 32, 1091-1102.	2.6	40
167	Role of Proteomics in Characterization of Biosimilar Products. , 2016, , 83-97.		1
168	Residual on column host cell protein analysis during lifetime studies of protein A chromatography. Journal of Chromatography A, 2016, 1461, 70-77.	3.7	25
169	Bridging the gap between PAT concepts and implementation: An integrated software platform for fermentation. Biotechnology Journal, 2016, 11, 164-171.	3.5	21
170	Artificial neural network (ANN)-based prediction of depth filter loading capacity for filter sizing. Biotechnology Progress, 2016, 32, 1436-1443.	2.6	14
171	Mechanistic understanding of fouling of protein A chromatography resin. Journal of Chromatography A, 2016, 1459, 78-88.	3.7	36
172	Continuous precipitation of process related impurities from clarified cell culture supernatant using a novel coiled flow inversion reactor (CFIR). Biotechnology Journal, 2016, 11, 1320-1331.	3.5	48
173	Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes?. Electrophoresis, 2016, 37, 2338-2346.	2.4	39
174	Assessing analytical comparability of biosimilars: GCSF as a case study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1032, 165-171.	2.3	23
175	Enablers for QbD implementation: Mechanistic modeling for ion-exchange membrane chromatography. Journal of Membrane Science, 2016, 500, 86-98.	8.2	25
176	Production of Protein Therapeutics in the Quality by Design (QbD) Paradigm. Topics in Medicinal Chemistry, 2016, , 41-67.	0.8	7
177	Quality by Design (QbD)-Based Process Development for Purification of a Biotherapeutic. Trends in Biotechnology, 2016, 34, 358-370.	9.3	46
178	Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics. AAPS Journal, 2016, 18, 689-702.	4.4	51
179	Continuous refolding of a biotech therapeutic in a novel Coiled Flow Inverter Reactor. Chemical Engineering Science, 2016, 140, 153-160.	3.8	39
180	Use of polymeric membranes for purification of an E. coli expressed biotherapeutic protein. Preparative Biochemistry and Biotechnology, 2016, 46, 183-191.	1.9	1

#	ARTICLE	IF	CITATIONS
181	Process Analytical Technologies in Biopharmaceutical Process Development. Journal of Chemical Technology and Biotechnology, 2015, 90, 213-214.	3.2	4
182	Fermentanomics: Relating quality attributes of a monoclonal antibody to cell culture process variables and raw materials using multivariate data analysis. Biotechnology Progress, 2015, 31, 1586-1599.	2.6	30
183	Application of process analytical technology for downstream purification of biotherapeutics. Journal of Chemical Technology and Biotechnology, 2015, 90, 228-236.	3.2	44
184	Role of Organic Modifier and Gradient Shape in RP-HPLC Separation: Analysis of GCSF Variants. Journal of Chromatographic Science, 2015, 53, 417-423.	1.4	17
185	Continuous Processing for Production of Biopharmaceuticals. Preparative Biochemistry and Biotechnology, 2015, 45, 836-849.	1.9	98
186	Rapid analysis of charge variants of monoclonal antibodies using non-linear salt gradient in cation-exchange high performance liquid chromatography. Journal of Chromatography A, 2015, 1406, 175-185.	3.7	43
187	Maximizing biomass concentration in baker's yeast process by using a decoupled geometric controller for substrate and dissolved oxygen. Bioresource Technology, 2015, 196, 160-168.	9.6	18
188	Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics. Trends in Biotechnology, 2015, 33, 381-387.	9.3	30
189	Comparison of PAT based approaches for making real-time pooling decisions for process chromatography – use of feed forward control. Journal of Chemical Technology and Biotechnology, 2015, 90, 341-348.	3.2	31
190	Biosimilars in India. Journal of Proteomics, 2015, 127, 71-72.	2.4	3
191	Mechanistic modeling of ion-exchange process chromatography of charge variants of monoclonal antibody products. Journal of Chromatography A, 2015, 1426, 140-153.	3.7	64
192	Integrating systems analysis and control for implementing process analytical technology in bioprocess development. Journal of Chemical Technology and Biotechnology, 2015, 90, 583-589.	3.2	50
193	Modeling of Filtration Processes – Microfiltration and Depth Filtration for Harvest of a Therapeutic Protein Expressed in Pichia pastoris at Constant Pressure. Bioengineering, 2014, 1, 260-277.	3.5	23
194	The Scare of Adventitious Agents in Therapeutic Products. PDA Journal of Pharmaceutical Science and Technology, 2014, 68, 192-192.	0.5	0
195	Avoiding antibody aggregation during processing: Establishing hold times. Biotechnology Journal, 2014, 9, 1195-1205.	3.5	60
196	Design of experiments applications in bioprocessing: Concepts and approach. Biotechnology Progress, 2014, 30, 86-99.	2.6	97
197	High-Throughput Process Development: I. Process Chromatography. Methods in Molecular Biology, 2014, 1129, 29-37.	0.9	2
198	High-Throughput Process Development: II. Membrane Chromatography. Methods in Molecular Biology, 2014, 1129, 39-44.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Aqueous Two-Phase-Assisted Precipitation of Proteins: A Platform for Isolation of Process-Related Impurities from Therapeutic Proteins. <i>Methods in Molecular Biology</i> , 2014, 1129, 101-110.	0.9	0
200	Mechanistic modeling of viral filtration. <i>Journal of Membrane Science</i> , 2014, 458, 96-103.	8.2	19
201	Analytical QbD: Development of a native gel electrophoresis method for measurement of monoclonal antibody aggregates. <i>Electrophoresis</i> , 2014, 35, 2163-2171.	2.4	20
202	Circular Dichroism Spectroscopy as a Tool for Monitoring Aggregation in Monoclonal Antibody Therapeutics. <i>Analytical Chemistry</i> , 2014, 86, 11606-11613.	6.5	105
203	Two-stage chromatographic separation of aggregates for monoclonal antibody therapeutics. <i>Journal of Chromatography A</i> , 2014, 1368, 155-162.	3.7	16
204	Guidance for performing multivariate data analysis of bioprocessing data: Pitfalls and recommendations. <i>Biotechnology Progress</i> , 2014, 30, 967-973.	2.6	38
205	QbD/PAT for bioprocessing: moving from theory to implementation. <i>Current Opinion in Chemical Engineering</i> , 2014, 6, 1-8.	7.8	75
206	A Practical Discussion of Risk Management for Manufacturing of Pharmaceutical Products. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2014, 68, 271-280.	0.5	1
207	Development of a low-cost, high-throughput native polyacrylamide gel electrophoresis (N-PAGE) protocol for lipoprotein sub-fractionation using Quality by Design approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 119-126.	2.8	4
208	Chemometrics application in biotech processes: assessing comparability across processes and scales. <i>Journal of Chemical Technology and Biotechnology</i> , 2014, 89, 1311-1316.	3.2	24
209	Capacity optimization and scheduling of a multiproduct manufacturing facility for biotech products. <i>Biotechnology Progress</i> , 2014, 30, 1221-1230.	2.6	6
210	Qualitative and quantitative examination of non-specific protein adsorption on filter membrane disks of a commercially available high throughput chromatography device. <i>Journal of Membrane Science</i> , 2014, 451, 312-318.	8.2	6
211	Establishing analytical comparability for "biosimilars" filgrastim as a case study. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 6569-6576.	3.7	20
212	Aggregation Kinetics for Monoclonal Antibody Products. <i>International Journal of Chemical Engineering and Applications (IJCEA)</i> , 2014, 5, 433-438.	0.3	2
213	Comparative Performance of Decoupled Input-Output Linearizing Controller and Linear Interpolation PID Controller: Enhancing Biomass and Ethanol Production in <i>Saccharomyces cerevisiae</i> . <i>Applied Biochemistry and Biotechnology</i> , 2013, 169, 1219-1240.	2.9	17
214	Multi-period scheduling of a multi-stage multi-product bio-pharmaceutical process. <i>Computers and Chemical Engineering</i> , 2013, 57, 95-103.	3.8	35
215	A novel multimodal chromatography based single step purification process for efficient manufacturing of an E. coli based biotherapeutic protein product. <i>Journal of Chromatography A</i> , 2013, 1314, 188-198.	3.7	37
216	Use of Computational Fluid Dynamics for Development and Scale-Up of a Helical Coil Heat Exchanger for Dissolution of a Thermally Labile API. <i>Organic Process Research and Development</i> , 2013, 17, 1311-1319.	2.7	1

#	ARTICLE	IF	CITATIONS
217	A novel aqueous two phase assisted platform for efficient removal of process related impurities associated with E. coli based biotherapeutic protein products. Journal of Chromatography A, 2013, 1307, 49-57.	3.7	14
218	High throughput process development (HTPD) platform for membrane chromatography. Journal of Membrane Science, 2013, 442, 245-253.	8.2	21
219	Chromatography process development in the quality by design paradigm I: Establishing a high-throughput process development platform as a tool for estimating characterization space for an ion exchange chromatography step. Biotechnology Progress, 2013, 29, 403-414.	2.6	48
220	Refolding of biotech therapeutic proteins expressed in bacteria: review. Journal of Chemical Technology and Biotechnology, 2013, 88, 1794-1806.	3.2	47
221	On-line implementation of decoupled input-output linearizing controller in Baker's yeast fermentation. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2013, 46, 259-264.	0.4	5
222	Optimization of a refolding step for a therapeutic fusion protein in the quality by design (QbD) paradigm. Journal of Separation Science, 2012, 35, 3160-3169.	2.5	45
223	Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. PDA Journal of Pharmaceutical Science and Technology, 2012, 66, 393-393.	0.5	30
224	Chemometrics applications in biotechnology processes: Predicting column integrity and impurity clearance during reuse of chromatography resin. Biotechnology Progress, 2012, 28, 1308-1314.	2.6	19
225	Knowledge Management and Process Monitoring of Pharmaceutical Processes in the Quality by Design Paradigm. Advances in Biochemical Engineering/Biotechnology, 2012, 132, 217-247.	1.1	5
226	Use of computational fluid dynamics as a tool for establishing process design space for mixing in a bioreactor. Biotechnology Progress, 2012, 28, 382-391.	2.6	42
227	Chemometrics applications in biotech processes: Assessing process comparability. Biotechnology Progress, 2012, 28, 121-128.	2.6	20
228	Long-term Scheduling of a Multi-stage Multi-product Bio-pharmaceutical Process. Computer Aided Chemical Engineering, 2012, 31, 1145-1149.	0.5	0
229	RECENT DEVELOPMENTS IN MEMBRANE-BASED SEPARATIONS IN BIOTECHNOLOGY PROCESSES: REVIEW. Preparative Biochemistry and Biotechnology, 2011, 41, 398-421.	1.9	80
230	High-throughput process development for biopharmaceutical drug substances. Trends in Biotechnology, 2011, 29, 127-135.	9.3	149
231	Chemometrics applications in biotech processes: A review. Biotechnology Progress, 2011, 27, 307-315.	2.6	52
232	Review of Computational fluid dynamics applications in biotechnology processes. Biotechnology Progress, 2011, 27, 1497-1510.	2.6	65
233	A statistical approach for estimation of significant variables in wet attrition milling. Powder Technology, 2011, 211, 46-53.	4.2	16
234	Large scale demonstration of a process analytical technology application in bioprocessing: Use of on-line high performance liquid chromatography for making real time pooling decisions for process chromatography. Biotechnology Progress, 2010, 26, 448-457.	2.6	37

#	ARTICLE	IF	CITATIONS
235	Application of near-infrared (NIR) spectroscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. <i>Biotechnology Progress</i> , 2010, 26, 527-531.	2.6	56
236	Process analytical technology (PAT) for biopharmaceutical products. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 137-154.	3.7	273
237	Process analytical technology (PAT) for biopharmaceutical products: Part I. concepts and applications. <i>Biotechnology and Bioengineering</i> , 2010, 105, 276-284.	3.3	190
238	Process analytical technology (PAT) for biopharmaceutical products: Part II. Concepts and applications. <i>Biotechnology and Bioengineering</i> , 2010, 105, 285-295.	3.3	140
239	Biosimilars. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2010, 64, 289.	0.5	0
240	Roadmap for implementation of quality by design (QbD) for biotechnology products. <i>Trends in Biotechnology</i> , 2009, 27, 546-553.	9.3	343
241	Follow-on protein products: scientific issues, developments and challenges. <i>Trends in Biotechnology</i> , 2009, 27, 698-705.	9.3	88
242	Case study and application of process analytical technology (PAT) towards bioprocessing: Use of tryptophan fluorescence as an online tool for making pooling decisions for process chromatography. <i>Biotechnology Progress</i> , 2009, 25, 1433-1439.	2.6	25
243	Quality by design for biopharmaceuticals. <i>Nature Biotechnology</i> , 2009, 27, 26-34.	17.5	654
244	Use of the design of experiments approach for the development of a refolding technology for progenipointin-1, a recombinant human cytokine fusion protein from <i>Escherichia coli</i> inclusion bodies. <i>Biotechnology and Applied Biochemistry</i> , 2009, 54, 85-92.	3.1	20
245	Case study and application of process analytical technology (PAT) towards bioprocessing: II. Use of ultra-performance liquid chromatography (UPLC) for making real-time pooling decisions for process chromatography. <i>Biotechnology and Bioengineering</i> , 2008, 101, 1366-1374.	3.3	47
246	Defining Process Design Space for Biotech Products: Case Study of <i>Pichia pastoris</i> Fermentation. <i>Biotechnology Progress</i> , 2008, 24, 655-662.	2.6	90
247	Application of Multivariate Data Analysis for Identification and Successful Resolution of a Root Cause for a Bioprocessing Application. <i>Biotechnology Progress</i> , 2008, 24, 720-726.	2.6	79
248	American Chemical Society: Division of Biochemical Technology (BIOT). <i>Biotechnology Progress</i> , 2008, 24, 487-487.	2.6	0
249	Case study and application of process analytical technology (PAT) towards bioprocessing: Use of online high-performance liquid chromatography (HPLC) for making real-time pooling decisions for process chromatography. <i>Biotechnology and Bioengineering</i> , 2008, 100, 306-316.	3.3	111
250	Generalizing a two-conformation model for describing salt and temperature effects on protein retention and stability in hydrophobic interaction chromatography. <i>Journal of Chromatography A</i> , 2007, 1157, 197-206.	3.7	42
251	Using Statistical Analysis for Setting Process Validation Acceptance Criteria for Biotech Products. <i>Biotechnology Progress</i> , 2007, 23, 55-60.	2.6	20
252	Application of Multivariate Analysis toward Biotech Processes: Case Study of a Cell-Culture Unit Operation. <i>Biotechnology Progress</i> , 2007, 23, 61-67.	2.6	84

#	ARTICLE	IF	CITATIONS
253	Harvest of a Therapeutic Protein Product from High Cell Density Fermentation Broths. <i>Biotechnology and Bioprocessing Series</i> , 2006, , 1-58.	0.0	7
254	Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth. <i>Biotechnology and Bioengineering</i> , 2006, 94, 91-104.	3.3	41
255	Life Span Studies for Chromatography and Filtration Media. , 2005, , 169-204.		3
256	Process characterization of the chromatographic steps in the purification process of a recombinant <i>Escherichia coli</i> -expressed protein. <i>Biotechnology and Applied Biochemistry</i> , 2003, 37, 51.	3.1	10
257	Cyclodextrins as selectivity enhancers in capillary zone electrophoresis of proteins. <i>Electrophoresis</i> , 1998, 19, 2285-2289.	2.4	8
258	QbD for Raw Materials. , 0, , 193-209.		9
259	Quality by Design: An Overview of the Basic Concepts. , 0, , 1-8.		14
260	Case Study on Definition of Process Design Space for a Microbial Fermentation Step. , 0, , 85-109.		14
261	Applications of Design Space for Biopharmaceutical Purification Processes. , 0, , 127-142.		5
262	A novel strategy for efficient expression of an antibody fragment in <i>Escherichia coli</i> : ranibizumab as a case study. <i>Journal of Chemical Technology and Biotechnology</i> , 0, , .	3.2	5
263	Elucidating chemical and disulfide heterogeneities in rituximab using reduced and non-reduced peptide mapping. <i>Journal of Separation Science</i> , 0, , .	2.5	0